103 related articles for article (PubMed ID: 2126464)
1. Antithrombin III: structural and functional aspects.
Mourey L; Samama JP; Delarue M; Choay J; Lormeau JC; Petitou M; Moras D
Biochimie; 1990 Aug; 72(8):599-608. PubMed ID: 2126464
[TBL] [Abstract][Full Text] [Related]
2. Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase.
Whisstock J; Lesk AM; Carrell R
Proteins; 1996 Nov; 26(3):288-303. PubMed ID: 8953650
[TBL] [Abstract][Full Text] [Related]
3. Serpin-glycosaminoglycan interactions.
Rein CM; Desai UR; Church FC
Methods Enzymol; 2011; 501():105-37. PubMed ID: 22078533
[TBL] [Abstract][Full Text] [Related]
4. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.
Schreuder HA; de Boer B; Dijkema R; Mulders J; Theunissen HJ; Grootenhuis PD; Hol WG
Nat Struct Biol; 1994 Jan; 1(1):48-54. PubMed ID: 7656006
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel recombinant serpin with potential antithrombotic properties.
Hopkins PC; Crowther DC; Carrell RW; Stone SR
J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic specificity of the reactive site loop of alpha1-antitrypsin, alpha1-antichymotrypsin, antithrombin III, and protease nexin I.
Djie MZ; Stone SR; Le Bonniec BF
J Biol Chem; 1997 Jun; 272(26):16268-73. PubMed ID: 9195929
[TBL] [Abstract][Full Text] [Related]
7. The complete amino acid sequence of bovine antithrombin (ATIII).
Mejdoub H; Le Ret M; Boulanger Y; Maman M; Choay J; Reinbolt J
J Protein Chem; 1991 Apr; 10(2):205-12. PubMed ID: 1930634
[TBL] [Abstract][Full Text] [Related]
8. Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin.
Le Bonniec BF; Guinto ER; Stone SR
Biochemistry; 1995 Sep; 34(38):12241-8. PubMed ID: 7547966
[TBL] [Abstract][Full Text] [Related]
9. Structural mobility of antithrombin and its modulation by heparin.
Carrell R; Skinner R; Jin L; Abrahams JP
Thromb Haemost; 1997 Jul; 78(1):516-9. PubMed ID: 9198206
[No Abstract] [Full Text] [Related]
10. Synthetic peptide inhibitors of complement serine proteases--III. Significant increase in inhibitor potency provides further support for the functional equivalence hypothesis.
Schasteen CS; Levine RP; McLafferty SA; Finn RF; Bullock LD; Mayden JC; Glover GI
Mol Immunol; 1991; 28(1-2):17-26. PubMed ID: 2011125
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin.
Mast AE; Enghild JJ; Pizzo SV; Salvesen G
Biochemistry; 1991 Feb; 30(6):1723-30. PubMed ID: 1704258
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins.
Baumann U; Huber R; Bode W; Grosse D; Lesjak M; Laurell CB
J Mol Biol; 1991 Apr; 218(3):595-606. PubMed ID: 2016749
[TBL] [Abstract][Full Text] [Related]
13. Kinetic Measurement of Serpin Inhibitory Activity by Real-Time Fluorogenic Biochemical Assay.
Yaron JR; Ambadapadi S; Zhang L; Lucas A
Methods Mol Biol; 2018; 1826():65-71. PubMed ID: 30194593
[TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of alpha(1)-proteinase inhibitor and antithrombin III: major serpins of rainbow trout (Oncorhynchuss mykiss) and carp (Cyprinus carpio) blood plasma.
Mickowska B
Fish Physiol Biochem; 2009 Jun; 35(2):231-40. PubMed ID: 19343519
[TBL] [Abstract][Full Text] [Related]
15. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site.
Skinner R; Abrahams JP; Whisstock JC; Lesk AM; Carrell RW; Wardell MR
J Mol Biol; 1997 Feb; 266(3):601-9. PubMed ID: 9067613
[TBL] [Abstract][Full Text] [Related]
16. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
Turk B; Brieditis I; Bock SC; Olson ST; Björk I
Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin: in control of coagulation.
Quinsey NS; Greedy AL; Bottomley SP; Whisstock JC; Pike RN
Int J Biochem Cell Biol; 2004 Mar; 36(3):386-9. PubMed ID: 14687916
[TBL] [Abstract][Full Text] [Related]
18. A peptide model for the heparin binding site of antithrombin III.
Lellouch AC; Lansbury PT
Biochemistry; 1992 Mar; 31(8):2279-85. PubMed ID: 1540583
[TBL] [Abstract][Full Text] [Related]
19. Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.
Chen Y; Lin L; Agyekum I; Zhang X; St Ange K; Yu Y; Zhang F; Liu J; Amster IJ; Linhardt RJ
J Pharm Sci; 2017 Apr; 106(4):973-981. PubMed ID: 28007564
[TBL] [Abstract][Full Text] [Related]
20. The cleaved and latent forms of antithrombin are normal constituents of blood plasma: a quantitative method to measure cleaved antithrombin.
Kjellberg M; Ikonomou T; Stenflo J
J Thromb Haemost; 2006 Jan; 4(1):168-76. PubMed ID: 16409466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
